Clinical Trial Update: A Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Modified Vaccinia Ankara (MVA)-Mosaic OR Ad26.Mos4.HIV Plus a Combination of Mosaic and Clade C gp140 Protein in Human Immunodeficiency Virus (HIV) Type 1 Infected Adults on Suppressive Antiretroviral Treatment [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating two regimens of Ad26.Mos4.HIV prime-boost followed by either MVA-Mosaic or a mosaic/Clade C gp140 protein combination in ART-suppressed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Ad26.Mos4.HIV (Adenovirus serotype 26 HIV vaccine (Mosaic))
• MVA-Mosaic (Modified Vaccinia Ankara HIV mosaic vaccine)
• Mosaic + Clade C gp140 protein (HIV envelope gp140 protein (mosaic and Clade C))

Snippet

Sponsor: Janssen Vaccines & Prevention B.V. | Conditions: Human Immunodeficiency Virus | Phase 1 | Status: COMPLETED